KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 2c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.91), $0.02 better than the analyst estimate of ($0.93).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• DSM-Firmenich AG (DSFIR:NA) PT Raised to EUR98 at Deutsche Bank
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce